Clinical trials: Neurocognitive Deficit
Mild Cognitive Impairment, Alzheimer's Disease
A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits
REINVENT is a non-interventional, multi-center, research network-based cross-over study evaluating the potential utility of a telehealth platform in improving the efficiency of clinical trials.
- Trial name
- REINVENT (NCT02778438)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Quintiles, Inc.
Schizophrenia
Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia
The purpose of this study is to test a new computerized training program as well as to find out whether the computer training might help people who have schizophrenia.
- Trial name
- TARA (NCT01773239)
- Testing
- TARA computer-based exercises
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Posit Science Corporation
Stroke, Attention Disorder
Virtual-reality Exercises for Alleviating Attention Deficits in Patients With Acquired Brain Injury
Stroke is the leading cause of long-term disability with an increasing incidence, especially in young adults. Among the cognitive difficulties following brain damage, deficits in attention are frequent and pervasive, affecting…
- Trial name
- NCT05728840
- Testing
- Immersive virtual reality gamified cognitive activities, Double neuropsychological standard activities
- Where
- Switzerland
- Volunteers
- 135 people
- Sponsor
- Mindmaze SA
Schizophrenia Disorders
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
This PoC study is designed to assess the cognitive effects of doses of AQW051 in patients with chronic stable schizophrenia.
- Trial name
- NCT01163227
- Testing
- AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses)
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Cognitive Decline, Focus Deficit
Effects of Auri Super Mushroom Daily Gummies on Cognitive Health
This is a single-arm, open-label, virtual clinical trial evaluating the cognitive health effects of Auri Super Mushroom Daily Gummies in a population of 35 adult participants over 8 weeks.
- Trial name
- NCT07198399
- Testing
- Auri Super Mushroom Daily Gummies
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Auri Nutrition
Schizophrenia, Cognition Disorders
The Effect of Nicotine on Arousal, Cognition and Social Cognition in Young and Elderly Healthy Subjects.
This study in young and elderly healthy subjects will investigate the effect of nicotine on arousal, cognitive task and social cognition after acute dose administration.
- Trial name
- NCT01181934
- Testing
- A643 (nicotine)
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Traumatic Brain Injury With Persistent Cognitive Deficits
An Extension Study Evaluating the Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits
Patients who completed the 12-week double blind protocol may enter this 26-week, open-label extension. This extension will give patients who complete the study an opportunity to receive treatment with open-label rivastigmine 3-12…
- Trial name
- NCT00219245
- Testing
- Rivastigmine
- Volunteers
- 157 people
- Sponsor
- Novartis
Multiple Sclerosis, Cognitive Impairment
Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment
This study evaluated the efficacy and safety of 10 cm² rivastigmine patch vs. placebo in cognitively impaired Multiple Sclerosis (MS) patients.
- Trial name
- EXCITING (NCT00881205)
- Testing
- Rivastigmine transdermal patch
- Where
- 49 sites in Germany
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia, Alzheimer's Disease
The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients
This study in patients with stable schizophrenia will investigate the effect of JNJ-39393406 on Event Related Potentials (Auditory Evoked Potential [AEP] P50, AEP P300 and Mismatch Negativity [MMN]) after single dose…
- Conditions
- Schizophrenia, Alzheimer's Disease, Cognition Disorders
- Trial name
- NCT01137799
- Testing
- JNJ-39393406
- Where
- 4 sites in Germany
- Volunteers
- 47 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Memory Impairment, Alzheimer's Disease
Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults
The purpose of this study is to determine whether scopolamine-induced cognitive impairment is attenuated by the administration of roflumilast in combination with donepezil.
- Trial name
- NCT02051335
- Testing
- Roflumilast, Donepezil, Scopolamine
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Schizophrenia
A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.
The purpose of this study is to determine if adding extended-release galantamine hydrobromide, compared with adding placebo, to current atypical antipsychotic therapy is well tolerated and effective in improving cognitive…
- Trial name
- NCT00077727
- Testing
- Extended-release galantamine hydrobromide
- Volunteers
- 107 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults
This study is a multi-site, double-blind, randomized, controlled clinical trial to assess the safety and effectiveness of plasticity-based, adaptive, computerized-based cognitive remediation treatment versus a computer-based…
- Trial name
- e-CAeSAR (NCT01422902)
- Testing
- Plasticity-based Cognitive Training, Non-plasticity-based Training
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Posit Science Corporation
Parenteral Nutrition Associated Liver Disease, Essential Fatty Acid Deficiency
Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)
This study will demonstrate Short-, mid-, and long-term safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this…
- Conditions
- Parenteral Nutrition Associated Liver Disease, Essential Fatty Acid Deficiency, Neurocognitive Deficit, Malnutrition
- Trial name
- NCT04807478
- Testing
- Omegaven® (fish oil triglycerides) Injectable Emulsion
- Sponsor
- Fresenius Kabi
Cognitive Deficits, Alzheimer Disease
Acupuncture Treatment for Improving Alzheimer's Dementia
Evaluate cognitive improvement pre amd post acupuncture treatment in patients with probable alzheimer's dementia as measured by MOCA score and also per form A( measure of patient's personal information). Also caregiver input.
- Trial name
- NCT04064021
- Testing
- Acupunture
- Sponsor
- N & S Neurology Center, A Medical Group, Inc
Schizophrenia
Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia
The purpose of this study is to demonstrate that AZD3480 improves cognition in patients with stable schizophrenia who are being treated with an atypical antipsychotic and who are active cigarette smokers, to assess the safety and…
- Trial name
- HALO (NCT00528905)
- Testing
- AZD3480
- Where
- 80 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Cognitive Decline, Cognitive Deficit
Validation Study SCOBES-AR
Purpose of the study The purpose of this study is to evaluate five tests to see if they are suitable for the early detection of cognitive impairment in people over the age of 60.
- Conditions
- Cognitive Decline, Cognitive Deficit, Cognitive Impairment
- Trial name
- NCT04204239
- Where
- Austria
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- FH Joanneum Gesellschaft mbH
Early Memory Loss, Mild Cognitive Impairment
NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)
This study will be an observational study in which patients who have been prescribed CerefolinNAC® are invited to participate in surveys regarding their experiences with CerefolinNAC®.
- Conditions
- Early Memory Loss, Mild Cognitive Impairment, Alzheimer's Disease, Vascular Dementia
- Trial name
- NCT01370954
- Testing
- CerefolinNAC®
- Where
- United States
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Pamlab, Inc.
Schizophrenia, Cognition Disorders
The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic Patients
This study in patients with stable schizophrenia will investigate the effect of nicotine on arousal, cognitive task and social cognition after acute dose administration.
- Trial name
- NCT01186471
- Testing
- A643 (nicotine)
- Volunteers
- 32 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Healthy, CVA
Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019.
DELPhI software developed for the analysis of EEG recordings in response to magnetic stimulation in relation to clinical data.
- Conditions
- Healthy, CVA, Hemorrhage, TBI (Traumatic Brain Injury)
- Trial name
- NCT04095377
- Testing
- No intervention, this is a retrospective study.
- Where
- Israel
- Volunteers
- 875 people, healthy volunteers welcome
- Sponsor
- QuantalX Neuroscience
Stroke, TBI
Characterization of the DELPhI System in Assessing Brain's Functionality in Different Neurological Disorders
We use Transcranial magnetic stimulation (TMS), combined with simultaneous registration of electroencephalograph (EEG),for examining human cortical functionality.
- Conditions
- Stroke, TBI, Fibromyalgia, PDD
- Trial name
- NCT03832413
- Testing
- DELPhI (TMS-EEG analysis)
- Where
- Israel
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- QuantalX Neuroscience